Global Non-Invasive Liquid Biopsy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Non-Invasive Liquid Biopsy Market Research Report 2024
Non-invasive liquid biopsy is to analyze and diagnose diseases such as cancer through blood or urine and other body fluids. At present, the main application area of liquid biopsy is the blood detection of tumors, that is, the use of blood to indicate tumor development and drug resistance and other information to guide individualized and precise treatment. Compared with existing tumor detection methods, liquid biopsy is non-invasive, can be detected frequently and repeatedly, and has rapid response capabilities. It has significant advantages and has great potential for application development.
According to MRAResearch’s new survey, global Non-Invasive Liquid Biopsy market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Invasive Liquid Biopsy market research.
Key companies engaged in the Non-Invasive Liquid Biopsy industry include Bio-Techne, Endress+Hauser, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp and Nucleix, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Non-Invasive Liquid Biopsy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-Invasive Liquid Biopsy market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Non-Invasive Liquid Biopsy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bio-Techne
Endress+Hauser
Exact Sciences Corporation
Lonza Group AG
MDxHealth
Merck KGaA
MutantDx
Norgen Biotek Corp
Nucleix
Oasis Diagnostics Corporation
OraSure Technologies
PerkinElmer
Predicine
Qiagen
Thermo Fisher Scientific
Zymo Research Corporation
Segment by Type
Stool Test
Urine Test
Saliva Test
Others
Hospital
Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-Invasive Liquid Biopsy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Non-Invasive Liquid Biopsy market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Invasive Liquid Biopsy market research.
Key companies engaged in the Non-Invasive Liquid Biopsy industry include Bio-Techne, Endress+Hauser, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp and Nucleix, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Non-Invasive Liquid Biopsy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Non-Invasive Liquid Biopsy market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Non-Invasive Liquid Biopsy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bio-Techne
Endress+Hauser
Exact Sciences Corporation
Lonza Group AG
MDxHealth
Merck KGaA
MutantDx
Norgen Biotek Corp
Nucleix
Oasis Diagnostics Corporation
OraSure Technologies
PerkinElmer
Predicine
Qiagen
Thermo Fisher Scientific
Zymo Research Corporation
Segment by Type
Stool Test
Urine Test
Saliva Test
Others
Segment by Application
Hospital
Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-Invasive Liquid Biopsy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source